Articles tagged with Tuberculosis
A third of the world's population is infected with M. tuberculosis, and two million people die from tuberculosis every year. New, improved vaccines or vaccination strategies are urgently needed to reduce the immense burden of this disease.
MDR-TB experts recommend new tools for testing, clinical trials of simplified treatments, and improved diagnosis strategies to overcome barriers. Pilot projects show promising results in low-income settings with treatment success rates of 59-83%.
Researchers have identified a new target for TB treatment, solving a long-standing puzzle about bacterial cell wall production. The discovery reveals molecules that could be developed into drugs to treat tuberculosis, particularly for multi-drug resistant strains.
Researchers found that if the first two TB patients are diagnosed within three months of each other, especially in urban areas with sub-Saharan African origin, there's a 56% chance of an outbreak. This information can help focus public health resources more efficiently.
Researchers Francesco Checchi and Les Roberts argue that an independent body is needed to accurately document death rates during humanitarian emergencies. Such a body could provide a basis for both humanitarian advocacy and political advocacy, and could help prevent the DRC experience from being repeated.
Researchers discovered that TB bacteria can form biofilms on surfaces, leading to genetic and physiological differences from lab-grown strains. This finding suggests a possible cause of TB relapses despite intensive treatment.
Researchers suggest that increasing white blood cell count or enhancing infected cells' interaction with the immune system could be effective strategies for developing vaccines or treatments specifically for elderly TB patients. Aging affects the immune response, leading to a slower and less effective fight against the infection.
Sub-Saharan Africa faces frequent stock interruptions of essential drugs for managing non-communicable diseases. Implementing standardized approaches to NCD management, as seen in TB control, can improve patient care and outcomes. A five-point framework called DOTS provides lessons for NCD control.
A growing number of 'pseudoepidemics' of false-positives for TB are occurring in the US Army due to universal testing with an inaccurate TST. The problem is most prevalent in regions with high TB rates, such as Iraq and Afghanistan.
A new TB treatment using Rifampin for four months is more effective than the current nine-month standard, saving healthcare systems $10,000 per patient. This shorter treatment also leads to better compliance rates and lower costs.
A new analysis of REMICADE for ulcerative colitis found that over 60% of patients achieved clinical response at week 8, with significant improvements maintained at week 30. The study also reported significant improvements in disease remission and mucosal healing.
A survey of infectious diseases physicians found that patients taking immune-modulating therapies are at risk for nontuberculosis mycobacterial infections, histoplasmosis, and invasive S. aureus infections. Clinicians should be vigilant for these infections, particularly in patients with underlying lung disease.
Researchers at the University of British Columbia have discovered how tuberculosis bacteria hide and multiply in human bodies. By identifying a key protein involved in this process, they are working towards therapies that can block its activity, leading to a more effective treatment for TB.
A new study from researchers at the University of Alabama at Birmingham found that carbon monoxide in air pollution and tobacco smoke triggers tuberculosis infection to shift into a dormant state. This dormant state is difficult to detect and treat, contributing to the spread of TB and its high mortality rate.
Researchers found that a portable anteroom HEPA filtration unit can effectively remove airborne microorganisms, including M. tuberculosis, from operating rooms. The study suggests that this unit can help prevent secondary transmission of airborne pathogens and improve patient and healthcare personnel safety.
Researchers have elucidated the mechanism of iron uptake system in M. tuberculosis, a promising target for intervention. The study reveals an exporter-importer system that exports siderophores and imports iron-bound forms, providing a crucial foothold to tame this deadly pathogen.
A study found that micronutrient supplementation reduced TB recurrence rates in patients undergoing chemotherapy. The study showed a 45% overall reduction and a 63% decrease for HIV-infected patients.
The National Institute of Allergy and Infectious Diseases (NIAID) has outlined a research agenda to combat drug-resistant tuberculosis, a major public health concern. The agenda focuses on developing reliable diagnostics, testing new drugs, and understanding the biology of TB-causing bacteria.
Rachel L. Stricof, a leading expert in infection prevention, has been recognized with the prestigious Carole DeMille Achievement Award for her dedication to improving health and patient safety. With over 30 years of experience, she has established innovative reporting systems and collaborated with policymakers to reduce HAI rates.
A new rapid diagnostic test can detect multidrug-resistant tuberculosis (MDR-TB) in high-burden settings like public health clinics more quickly and accurately than conventional methods. This improvement enables proper treatment to begin promptly, reducing the risk of transmission.
Researchers have developed an assay to identify antibodies specific to Mycobacterium avium complex (MAC), distinguishing MAC-related pulmonary disease from tuberculosis in under eight hours. The test showed high sensitivity and specificity, reducing the risk of misdiagnosis and inappropriate treatment.
Researchers at the University of Leicester have discovered that TB bacteria accumulate body fat to aid survival during transmission, increasing resistance to anti-TB drugs. This finding challenges established views on bacterial transmission and offers new insights into developing targeted treatments.
Researchers identified a genetic variant associated with severe tuberculosis (TB) in Vietnam, highlighting the importance of studying host-pathogen interactions. The study suggests that understanding genetic susceptibility to infectious diseases may lead to more targeted treatments and vaccines.
The University of Pittsburgh Center for Vaccine Research has received a $11.4 million grant to study tuberculosis using new imaging technologies. The goal is to develop more effective treatments that can be tailored to individual patients, potentially improving survival rates and curtailing the global TB epidemic.
Researchers at the University of Leicester have discovered how TB bacteria becomes resistant to isoniazid, a key treatment for the disease. The study reveals that mutations in bacterial enzymes protect it from the treatment, highlighting the importance of understanding drug resistance.
A new aerosol version of the most common TB vaccine administered directly to the lungs via oral mist provides significantly better protection against TB in experimental animals. The vaccine could offer a safer, more consistent treatment option with reduced need for refrigerated storage.
A new blood test, ELISpot-Plus, in conjunction with a skin test, can rule out tuberculosis infection within 48 hours, providing a much quicker result than existing methods. This combination enables doctors to diagnose TB more accurately and begin investigating other possible explanations for patients' symptoms.
A new TB screening test based on ELISPOT test has shown high sensitivity and specificity in detecting latent TB infection in HIV-infected individuals. The test was compared to the traditional tuberculin skin test (TST) and found to be more sensitive, but its effectiveness in severely immunosuppressed individuals remains unclear.
A new guideline for treating dementia emphasizes the importance of individualized assessment and treatment based on a patient's specific medication regimen. Researchers also developed two new blood tests to diagnose latent tuberculosis, finding that one test is more sensitive than traditional methods.
A six-year vitamin E supplementation increased TB risk by 72% in male smokers with high dietary vitamin C intake. Vitamin E had no effect on those with low dietary vitamin C intake.
India is experiencing a devastating tobacco-related disease crisis, with approximately 1 million deaths expected each year from 2010 to 2019. The study reveals that smoking causes nearly one in five male deaths and one in twenty female deaths at ages 30-69.
The US is likely to miss its goal of eliminating tuberculosis by 2010 due to high latent TB infection rates among certain groups, including those living below the poverty line and foreign-born individuals.
The grant will support research into the proteins on TB bacteria's surface that are vital for infection, aiming to develop a map for drug developers. The goal is to create a new family of TB drugs that can effectively target the disease in a new way.
Researchers have developed a key small molecule inhibitor targeting 'virulence factors' used by bacteria to thrive, offering an alternative means of stopping TB, leprosy, and other bacterial illness. The findings highlight a paradigm shift in infectious disease research beyond antimicrobials like antibiotics.
A Cornell research team used gene chips to study Mycobacterium tuberculosis and found that the bacteria's genes are activated after being engulfed by a macrophage. The study also compared the responses of M. tuberculosis to BCG, finding that BCG may be less capable of protecting itself once inside a macrophage.
A new study from Yale University suggests that preventing half of new XDR TB cases can be achieved through inexpensive infection control measures, including reducing hospital overcrowding and improving ventilation. This could potentially save millions of lives globally.
Researchers have found that rifapentine, an older antibiotic, is a potent treatment for tuberculosis when used at high doses. Clinical trials are underway to test its effectiveness in reducing treatment time from six months to three months or less.
Weill Cornell Medical College has received grants to develop innovative TB drugs and treatments, with a focus on killing or interfering with the TB organism in its non-replicating phase. The research aims to shorten TB therapy from six months to just a couple of weeks, while also addressing emerging drug-resistant forms.
Researchers found a 500,000-year-old human fossil in Turkey with evidence of Leptomeningitis tuberculosa, a form of brain tuberculosis. The discovery suggests that dark-skinned people migrating from low latitudes may be more vulnerable to the disease due to vitamin D deficiency.
Researchers sequence genomes of multi-drug resistant and drug-sensitive TB isolates, revealing few genetic differences that contribute to drug resistance. The findings shed light on the genetic factors driving TB drug resistance and lay the groundwork for a rapid diagnostic test.
TB drug resistance is a growing concern, with millions of cases worldwide each year. Doctors Without Borders advocates for increased funding and collaboration to develop new treatments.
Researchers in Norway analyzed TB cases between 1993 and 2005, finding little evidence of spread among native-born citizens. Instead, immigrants brought more strains, while native infections decreased, suggesting immigration does not significantly contribute to TB transmission.
Researchers found that a combination of infection control measures, including masks, reduced hospitalization time, and improved ventilation, could prevent nearly half of new XDR tuberculosis cases. The study's findings highlight the need for immediate action to address the growing epidemic in South Africa.
Researchers have made significant breakthroughs in various medical fields. A new tattooing procedure has improved the precision of VATS, while collaborative efforts have accelerated antibiotic timing. Modified Tai Chi exercises may also help patients with COPD, while human fibrin sealant shows promise for lung resection surgery.
A new TB drug, SQ109, has been given special status by the US and European regulators for its potential to combat drug-resistant strains of M. tuberculosis. The orphan designation will accelerate clinical testing of the drug, which may lead to simpler and more effective treatment regimens for the disease.
SQ109 shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant TB bacteria. The treatment also synergizes with other TB drugs in experimental animal models, offering new combinations with greater activity than current standard care.
A study found that a strain of extensively drug-resistant tuberculosis in South Africa developed resistance to multiple drugs due to inadequate drug susceptibility testing. The authors emphasize the need for increased use of drug resistance surveillance programs to prevent further development of XDR TB.
The WHO EURO region's Ministerial Forum on tuberculosis must consider the global impact of the disease and take collective action to control poverty and inequality. The authors propose a six-pronged approach to tackle the threat, including addressing trade policies and global poverty.
Researchers developed a computational model to predict TB reactivation causes and developed a TNF-modulating agent to balance inflammation reduction with infection resistance. Modifying anti-TNF treatment dosages and timing or using TB antibiotics before treatment can also prevent reactivation, according to the study.
Researchers are developing a portable mass spectrometer to diagnose tuberculosis (TB) with greater sensitivity than smear microscopy. The device could automate the process, making it more widely available in resource-poor settings where TB kills two million people annually.
Dr. Gumbo's award aims to develop a treatment regimen based on blocking the mechanisms that tuberculosis bacteria use to avoid being killed by antibiotics, potentially reducing treatment time from months to weeks.
A new antibiotic combination could dramatically shorten TB treatment time from six months to four months, with a cure rate increasing by 17 percent after two months of therapy. Researchers say the shorter treatment period may also reduce transmission and improve drug compliance.
A study by University of Alberta researchers suggests that all children adopted from outside North America should be screened for tuberculosis. The study found that 40% of foreign-born children under five years old with TB in Canada were international adoptees, highlighting the importance of systematic screening.
A decision aid for patients with diabetes was developed by Victor Montori and colleagues, enabling them to make informed choices about statin use. The tool created a conversation about medications, allowing patients to weigh the benefits and risks of statins.
A study of US medical residents found that nearly half of them incorrectly answered questions about diagnosing and managing tuberculosis (TB). The residents showed particular difficulty in answering questions related to latent TB, the progression from latent to active disease, and interpreting diagnostic tests for patients with active TB.
Researchers developed a new vaccine strategy that uses a protein-free M. Tuberculosis strain to activate immune cells, providing increased protection against TB. A study found that vaccination with this strain provided better protection than the existing BCG vaccine.
A survey of 131 medical residents found that they scored poorly in diagnosing and managing tuberculosis, with a median score of just 55 percent. Despite this, most residents understood the main facts about how the disease is transmitted, highlighting the need for improved training in outpatient settings.
A genetically altered strain of tuberculosis has been developed that elicits a stronger immune response than the current vaccine, improving survival of infected animals. The new vaccine may help replace BCG, which is largely ineffective, and could lead to significant reductions in TB-related mortality.
The new vaccine uses a virulent M. tuberculosis strain with genes knocked out to prevent apoptosis of mammalian cells, eliciting a strong and long-lasting T-cell response. This approach demonstrates superior protection compared to the standard BCG vaccine in animal models.
Researchers have discovered a new vaccine strategy that effectively protects mice and guinea pigs from tuberculosis, targeting immune cells known as CD8+ T cells. The study suggests a potential breakthrough in developing a more effective vaccine for all individuals, including adolescents and adults.